Kezar Life Sciences, Inc. (KZR)
7.29
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
Kezar Life Sciences SG&A Expense (TTM) : 18.27M for March 31, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 18.27M |
| December 31, 2025 | 18.51M |
| September 30, 2025 | 20.81M |
| June 30, 2025 | 21.72M |
| March 31, 2025 | 22.30M |
| December 31, 2024 | 23.39M |
| September 30, 2024 | 23.61M |
| June 30, 2024 | 26.69M |
| March 31, 2024 | 26.87M |
| December 31, 2023 | 26.54M |
| September 30, 2023 | 25.96M |
| June 30, 2023 | 22.23M |
| March 31, 2023 | 21.42M |
| December 31, 2022 | 20.15M |
| September 30, 2022 | 19.30M |
| June 30, 2022 | 18.20M |
| March 31, 2022 | 16.90M |
| December 31, 2021 | 15.72M |
| September 30, 2021 | 14.35M |
| Date | Value |
|---|---|
| June 30, 2021 | 13.67M |
| March 31, 2021 | 12.71M |
| December 31, 2020 | 11.97M |
| September 30, 2020 | 11.58M |
| June 30, 2020 | 10.89M |
| March 31, 2020 | 10.62M |
| December 31, 2019 | 9.979M |
| September 30, 2019 | 9.166M |
| June 30, 2019 | 8.165M |
| March 31, 2019 | 7.457M |
| December 31, 2018 | 6.589M |
| September 30, 2018 | 4.836M |
| June 30, 2018 | 3.871M |
| March 31, 2018 | 2.149M |
| December 31, 2017 | 1.061M |
| September 30, 2017 | 1.061M |
| June 30, 2017 | 0.426M |
| March 31, 2017 | 0.426M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| NovelStem International Corp. | 0.1201M |
| Brainstorm Cell Therapeutics, Inc. | 6.474M |
| Summit Therapeutics, Inc. | 306.10M |
| Protara Therapeutics, Inc. | 23.56M |
| Clene, Inc. | 7.873M |